NasdaqGS - Delayed Quote USD

Alkermes plc (ALKS)

24.65 +0.39 (+1.61%)
At close: April 24 at 4:00 PM EDT
26.74 +2.09 (+8.48%)
Pre-Market: 8:00 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,663,405.00
1,663,405.00
1,111,795.00
1,173,751.00
1,038,756.00
Cost of Revenue
253,037.00
253,037.00
218,068.00
197,323.00
178,316.00
Gross Profit
1,410,368.00
1,410,368.00
893,727.00
976,428.00
860,440.00
Operating Expense
996,246.00
996,246.00
899,816.00
878,682.00
972,867.00
Operating Income
414,122.00
414,122.00
-6,089.00
97,746.00
-112,427.00
Net Non Operating Interest Income Expense
7,822.00
7,822.00
-5,411.00
-8,811.00
-1,699.00
Other Income Expense
-425.00
-425.00
-19,628.00
-1,208.00
17,589.00
Pretax Income
421,519.00
421,519.00
-31,128.00
87,727.00
-96,537.00
Tax Provision
-97,638.00
-97,638.00
2,024.00
11,326.00
14,324.00
Net Income Common Stockholders
355,757.00
355,757.00
-158,267.00
-48,169.00
-110,861.00
Diluted NI Available to Com Stockholders
355,757.00
355,757.00
-158,267.00
-48,169.00
-110,861.00
Basic EPS
2.14
2.14
-0.97
-0.30
-0.70
Diluted EPS
2.10
2.10
-0.97
-0.30
-0.70
Basic Average Shares
166,223.00
166,223.00
163,742.00
160,942.00
158,803.00
Diluted Average Shares
169,730.00
169,730.00
163,742.00
164,753.00
158,803.00
Total Operating Income as Reported
414,122.00
414,122.00
-6,089.00
97,746.00
-112,427.00
Total Expenses
1,249,283.00
1,249,283.00
1,117,884.00
1,076,005.00
1,151,183.00
Net Income from Continuing & Discontinued Operation
355,757.00
355,757.00
-158,267.00
-48,169.00
-110,861.00
Normalized Income
519,157.00
519,157.00
-15,969.50
77,643.77
-113,740.85
Interest Income
30,854.00
30,854.00
7,629.00
2,408.00
6,960.00
Interest Expense
23,032.00
23,032.00
13,040.00
11,219.00
8,659.00
Net Interest Income
7,822.00
7,822.00
-5,411.00
-8,811.00
-1,699.00
EBIT
444,551.00
444,551.00
-18,088.00
98,946.00
-87,878.00
EBITDA
519,478.00
519,478.00
59,774.00
177,598.00
-6,024.00
Reconciled Cost of Revenue
213,799.00
213,799.00
176,569.00
156,819.00
135,914.00
Reconciled Depreciation
74,927.00
74,927.00
77,862.00
78,652.00
81,854.00
Net Income from Continuing Operation Net Minority Interest
519,157.00
519,157.00
-33,152.00
76,401.00
-110,861.00
Total Unusual Items Excluding Goodwill
--
--
-21,750.00
-1,427.00
3,945.00
Total Unusual Items
--
--
-21,750.00
-1,427.00
3,945.00
Normalized EBITDA
519,478.00
519,478.00
81,524.00
179,025.00
-9,969.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-4,567.50
-184.23
1,065.15
12/31/2020 - 7/16/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IRWD Ironwood Pharmaceuticals, Inc.
8.10
-2.53%
 
NBIX Neurocrine Biosciences, Inc.
138.97
-0.80%
 
COLL Collegium Pharmaceutical, Inc.
35.48
-1.28%
 
ITCI Intra-Cellular Therapies, Inc.
73.12
-1.20%
 
SUPN Supernus Pharmaceuticals, Inc.
30.26
+1.04%
 
EGRX Eagle Pharmaceuticals, Inc.
4.5500
-4.61%
 
AMPH Amphastar Pharmaceuticals, Inc.
41.00
+0.22%
 
LFCR Lifecore Biomedical, Inc.
6.33
-1.86%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.62
-0.34%
 
HCM HUTCHMED (China) Limited
18.41
+0.88%